Table I.
Pathological and clinical data of the arrayed prostate cancer samples.
| Variables | Study cohort on TMAa, n | Biochemical relapse, n (%) |
|---|---|---|
| Follow-up | 11,152 | 2,769 (24.8) |
| Mean/median (months) | 64.4/60.0 | – |
| Age (years) | ||
| ≤50 | 323 | 81 (25.1) |
| 51–59 | 2,696 | 705 (26.1) |
| 60–69 | 6,528 | 1,610 (24.7) |
| ≥70 | 1,498 | 370 (24.7) |
| Pretreatment PSA (ng/ml) | ||
| <4 | 1,585 | 242 (15.3) |
| 4–10 | 7,480 | 1,355 (18.1) |
| >10–20 | 2,412 | 737 (30.6) |
| >20 | 812 | 397 (48.9) |
| pT stage (AJCC 2002) | ||
| pT2 | 8,187 | 1,095 (13.4) |
| pT3a | 2,660 | 817 (30.7) |
| pT3b | 1,465 | 796 (54.3) |
| pT4 | 63 | 51 (81.0) |
| Gleason grade | ||
| ≤3+3 | 2,297 | 230 (10.0) |
| 3+4 | 6,679 | 1,240 (18.6) |
| 3+4 Tertiary 5 | 433 | 115 (26.6) |
| 4+3 | 1,210 | 576 (47.6) |
| 4+3 Tertiary 5 | 646 | 317 (49.1) |
| ≥4+4 | 416 | 348 (83.7) |
| pN stage | ||
| pN0 | 6,970 | 1,636 (23.5) |
| pN+ | 693 | 393 (56.7) |
| Surgical margin | ||
| Negative | 9,990 | 1,848 (18.5) |
| Positive | 2,211 | 853 (38.6) |
a
Numbers do not always add up to 12,432 in different categories because of cases with missing data. AJCC, American Joint Committee on Cancer; PSA, prostate-specific antigen; TMA, tissue microarray.